Health and Healthcare

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

141 Articles

Chris Lange | Oct 16, 2014 at 2:05 PM EDT

Ebola Stocks on the Move

Investors fan the flames of Ebola fears in the market, enabling these biotech companies to profit from these fears.

Jon C. Ogg | Oct 8, 2014 at 12:20 PM EDT

Ebola Drug Stocks React Wildly to Dallas Patient Death

The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola…

Chris Lange | Oct 6, 2014 at 2:05 PM EDT

Reality Sets in for Ebola Drug Hopefuls

Tekmira Pharmaceuticals downgrade also drags down Sarepta Therapeutics and BioCryst Pharmaceuticals.

Jon C. Ogg | Oct 1, 2014 at 9:55 AM EDT

Major Fallout Stocks After Confirmed Ebola Case in United States

With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides…

Jon C. Ogg | Sep 30, 2014 at 5:16 PM EDT

Reaction to Confirmed Ebola Case in U.S. — UPDATED

News has hit of the first confirmed Ebola case in the United States. Companies involved in potential drugs for Ebola…

Jon C. Ogg | Sep 24, 2014 at 11:20 AM EDT

Analyst Now Sees 75% Upside in Sarepta

Credit Suisse's $36 price target on Sarepta Therapeutics effectively calls for close to 75% upside.

Jon C. Ogg | Sep 24, 2014 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Auxilium, Ericsson, GoldCorp, McDonald’s, Micron, Sarepta and More

These are the top analyst upgrades, downgrades and initiations covered by 24/7 Wall St. for Wednesday, September 24, 2014.

Jon C. Ogg | Aug 1, 2014 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: Expedia, Hyatt, Ocwen, Strayer, SunPower, 3D Systems and More

These are the top analyst upgrades, downgrades and initiations from Wall Street analysts for Friday. They include Expedia, Hyatt Hotels,…

Jon C. Ogg | Jul 22, 2014 at 8:35 AM EDT

Top Analyst Upgrades and Downgrades: Allergan, Amazon, Chipotle, Netflix, QIWI, Sarepta and More

These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Tuesday, July 22, 2014. They include…

Jon C. Ogg | Apr 23, 2014 at 10:50 AM EDT

Companies Betting on the Next 10 Blockbuster Drugs

24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in…

Paul Ausick | Apr 21, 2014 at 10:10 AM EDT

Odds of Sarepta Drug Approval Rise Sharply

Shares of Sarepta Therapeutics went through the roof Monday morning following an announcement that it plans to have a New…

Jon C. Ogg | Jan 27, 2014 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: Cisco, Lululemon, Nokia, Peabody, Xerox and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, January 27, 2014.…

Jon C. Ogg | Dec 23, 2013 at 8:40 AM EST

Top Analyst Upgrades and Downgrades: BlackBerry, Five Below, Micron, Tiffany and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms Monday, December 23, 2013.

Paul Ausick | Apr 16, 2013 at 4:42 PM EDT

Market Close: Big Winners & Losers for April 16, 2013

thinkstockHere are today’s five biggest gaining stocks at closing: Mattersight Corp. (NASDAQ: MATR) is up 29.4% at $2.33. Comstock Holding…

Jon C. Ogg | Apr 4, 2013 at 6:56 AM EDT

Nineteen Stocks Expected to Rise 50% to 100% — or More

Investors and traders alike always seem to be on the lookout for new investment ideas. With the S&P 500 and the…

1 … 7 8 9 10

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Ebola Stocks on the Move

Ebola Drug Stocks React Wildly to Dallas Patient Death

Reality Sets in for Ebola Drug Hopefuls

Major Fallout Stocks After Confirmed Ebola Case in United States

Reaction to Confirmed Ebola Case in U.S. — UPDATED

Analyst Now Sees 75% Upside in Sarepta

Top Analyst Upgrades and Downgrades: Auxilium, Ericsson, GoldCorp, McDonald’s, Micron, Sarepta and More

Top Analyst Upgrades and Downgrades: Expedia, Hyatt, Ocwen, Strayer, SunPower, 3D Systems and More

Top Analyst Upgrades and Downgrades: Allergan, Amazon, Chipotle, Netflix, QIWI, Sarepta and More

Companies Betting on the Next 10 Blockbuster Drugs

Odds of Sarepta Drug Approval Rise Sharply

Top Analyst Upgrades and Downgrades: Cisco, Lululemon, Nokia, Peabody, Xerox and More

Top Analyst Upgrades and Downgrades: BlackBerry, Five Below, Micron, Tiffany and More

Market Close: Big Winners & Losers for April 16, 2013

Nineteen Stocks Expected to Rise 50% to 100% — or More

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

Ebola Stocks on the Move

Ebola Drug Stocks React Wildly to Dallas Patient Death

Reality Sets in for Ebola Drug Hopefuls

Major Fallout Stocks After Confirmed Ebola Case in United States

Reaction to Confirmed Ebola Case in U.S. — UPDATED

Analyst Now Sees 75% Upside in Sarepta

Top Analyst Upgrades and Downgrades: Auxilium, Ericsson, GoldCorp, McDonald’s, Micron, Sarepta and More

Top Analyst Upgrades and Downgrades: Expedia, Hyatt, Ocwen, Strayer, SunPower, 3D Systems and More

Top Analyst Upgrades and Downgrades: Allergan, Amazon, Chipotle, Netflix, QIWI, Sarepta and More

Companies Betting on the Next 10 Blockbuster Drugs

Odds of Sarepta Drug Approval Rise Sharply

Top Analyst Upgrades and Downgrades: Cisco, Lululemon, Nokia, Peabody, Xerox and More

Top Analyst Upgrades and Downgrades: BlackBerry, Five Below, Micron, Tiffany and More

Market Close: Big Winners & Losers for April 16, 2013

Nineteen Stocks Expected to Rise 50% to 100% — or More

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

Featured Reads

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It